Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
05 août 2024 08h00 HE
|
Clene Inc.
SALT LAKE CITY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene to Present at the Emerging Growth Conference
12 juil. 2024 10h34 HE
|
Clene Inc.
SALT LAKE CITY, July 12, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS
11 juil. 2024 09h00 HE
|
Clene Inc.
SALT LAKE CITY, July 11, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene Announces 1-for-20 Reverse Stock Split
09 juil. 2024 08h00 HE
|
Clene Inc.
SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference
24 juin 2024 08h00 HE
|
Clene Inc.
SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
21 juin 2024 07h09 HE
|
Clene Inc.
CNM-Au8 demonstrated neuroprotective effects in an in vitro model of Rett Syndrome, a rare pediatric neurodevelopmental diseaseCNM-Au8 also demonstrated rescue of mitochondrial deficits in induced...
Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting
18 juin 2024 07h00 HE
|
Clene Inc.
Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline (hazard ratio: 0.431, p=0.0002)Average of 28% NfL...
Clene to Present at the Emerging Growth Conference
05 juin 2024 08h00 HE
|
Clene Inc.
SALT LAKE CITY, June 05, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
28 mai 2024 07h30 HE
|
Clene Inc.
First patient, first visit is planned for early June 2024Enrollment has been expanded by 80% to a maximum of 180 participants‘Real-world’ drug efficacy data will be collected by monitoring potential...
Clene to Present at Upcoming May Conferences
14 mai 2024 08h00 HE
|
Clene Inc.
SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...